An Approach to the Office-Based Practice of Food Oral Immunotherapy

J Allergy Clin Immunol Pract. 2021 May;9(5):1826-1838.e8. doi: 10.1016/j.jaip.2021.02.046. Epub 2021 Mar 5.

Abstract

Oral immunotherapy (OIT) provides an active treatment option for patients with food allergies. OIT may improve quality of life and raise the threshold at which a patient with food allergy may react to an allergen, but it is a rigorous therapy that requires a high degree of commitment by the clinician, patients, and families. Recent guidelines from the Canadian Society for Allergy and Clinical Immunology have provided a framework for the ethical, evidence-based, and patient-oriented clinical practice of OIT, and the European Academy of Allergy, Asthma, and Immunology guidelines have also recommended that OIT can be used as a potential treatment. The recent Food and Drug Administration approval of an OIT pharmaceutical has accelerated the adoption of OIT. This review provides a summary of the recent Canadian Society for Allergy and Clinical Immunology guidelines and a consensus of practical experience of clinicians across the United States and Canada related to patient selection, office and staff preparation, the general OIT process, OIT-related reaction management, and treatment outcomes.

Keywords: Adverse reactions; OIT (oral immunotherapy); Practical experience; Protocol considerations; Shared decision making.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Allergens
  • Canada
  • Desensitization, Immunologic*
  • Food Hypersensitivity* / therapy
  • Humans
  • Immunotherapy
  • Quality of Life

Substances

  • Allergens